So far, although hyperactivation in mTOR and mutation in oncogene Kras had been respectively discussed a lot in multiple malignancies, it is still unclear the synergistic effect of them in HCC, and potential therapeutic target for HCC with this molecular background. The gene discussed is KRAS; the disease is hepatocellular carcinoma.